## Previously reported target-adverse event associations in the context of secondary pharmacology profiling

Extract targets and associated adverse effects from three<sup id="a1">[1-3](#f1)</sup> safety target panels and map them to the MedDRA vocabulary.

<b id="f1">1</b> Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012;11(12):909‐922. doi: [10.1038/nrd3845](https://doi.org/10.1038/nrd3845) [↩](#a1)  
<b id="f2">2</b> Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421‐1433. doi: [10.1016/S1359-6446(05)03632-9](https://doi.org/10.1016/S1359-6446(05)03632-9) [↩](#a1)  
<b id="f3">3</b> Lynch JJ 3rd, Van Vleet TR, Mittelstadt SW, Blomme EAG. Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods. 2017;87:108‐126. doi: [10.1016/j.vascn.2017.02.020](https://doi.org/10.1016/j.vascn.2017.02.020) [↩](#a1)  